Cardio drug at The Medicines Co gets the heave-ho. (But they prefer PCSK9 anyway.)
The Medicines Company’s cardio pipeline is being pared back to its showcase PCSK9 project following a Phase II failure of their atherosclerosis drug MDCO-216.
MDCO-216 was tested in a 120-patient study to see how effective it would be in spurring cholesterol efflux. It’s built from the ApoA-1 Milano protein — discovered in a town in northern Italy where residents had low levels of “good” HDL but with little or no atherosclerotic plaque buildup associated with coronary artery disease — and a phospholipid.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
